On September 28 of this year, the FDA’s Office of Prescription Drug Promotion (“OPDP”) issued an Untitled Letter to Evolus, Inc. (“Evolus”) concerning promotional materials the company posted on its Instagram page. Evolus is the manufacturer of Jeuveau, a prescription injectable neurotoxin “that temporarily smooths moderate to severe frown lines between the eyebrows.” The FDA was alerted to the advertisement through FDA Form 2253 (the required submission form for pharmaceutical promotional materials) and through the FDA’s Bad Ad Program.
The advertisement features a young woman named Josephine who participates in a patient testimonial about her use of the product. During the interview, she states, “I’m excited about getting rid of my lines…I’m ready to, like, not have them so much.” The advertisement then provides images depicting her progress from Day 0 to Day 2 of product use. While the before-and-after images are displayed on the screen, Josephine can be heard saying, “I feel really good. I’m really surprised at how quickly it’s kicking in! And I’m feeling like the line between my eyebrows is gone.” Additionally, the following text appears below the images of Josephine’s face in the Day 0 and Day 2 comparison: “About 50% of patients begin showing improvement after two days. Most patients (~69%) achieve complete results by day 30.”
The “comments section” of the post continuously displays the following text during the interview: “Lines today. Blurred in as little as 2 days…Nope. You’re not seeing things. Jeuveau really does work like that. Josephine is only one of the many patients who loved their results with Jeuveau. ‘I feel really good. I’m really surprised at how quickly it kicked in!’ With our iconic fast-acting results…”
After reviewing the advertisement, the FDA determined that it was “misbranded” under the Federal Food, Drug, and Cosmetic Act (“Act”) because (1) its labeling was “false or misleading”; (2) it failed to include “such other information in brief summary relating to side effects, contraindications, and effectiveness”; and (3) it failed “to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug, taking into account all implementing factors such as typography, layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve emphasis.” Furthermore, the FDA stated that this product advertisement presented a unique public health concern because it failed to adequately present the serious potential adverse effects associated with use of the product.
The FDA made four arguments supporting its determination that the product was “misbranded” under the Act.
First, the promotional materials indicated that using Jeuveau will get “rid of” facial lines, which will ultimately be “gone.” However, the FDA argued that the Prescribing Information clearly states that the product is only indicated for the “temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.” Making the claim that a product indefinitely gets “rid of” facial lines when it is only indicated for temporary treatment is, according to OPDP’s letter, misleading.
Second, the efficacy of the product was based on the primary endpoint measured on Day 30. Thus, the Day 2 measurements in the pivotal clinical trial were simply exploratory and were not subject to statistical analysis. However, as shown above, the results from Day 2 and Day 30 are presented as if they have equal weight. As stated clearly in the letter, “the inclusion of claims and presentations related to the exploratory endpoint at Day 2 conflates the measures of response and confounds consumers’ understanding of the efficacy of Jeuveau.”
Third, the FDA claimed that the advertisement indicates that Jeuveau, a prescription drug with serious potential side effects, is comparable to a beauty product. To that end, the FDA highlighted the following statement: “…it’s no wonder Jeuveau is making moves to Studio @IPSY for our Blur The Lines Masterclass. Because in 2026, we’re blurring the lines between what’s found in your beauty bag and what happens in the treatment room. [syringe icon][lipstick icon].” Thus, the FDA stated that the “suggestion that lines are blurred between Jeuveau, a prescription product, and an over-the-counter cosmetic is especially problematic from a public health perspective given the serious risks associated with the use of the product.”
Finally, the FDA determined that, by placing safety and risk information at the end of the reel, the advertisement failed to present “information related to the side effects and contraindications” with a “prominence and readability reasonably comparable with the presentation of information relating to the benefits of Jeuveau.”
Industry should take note of two points. First, promotional materials should not present information in a way that conflates actual clinical endpoints with merely exploratory endpoints. Second, presenting a serious prescription drug with a boxed warning as if it were simply another beauty product easily retrievable from your bag risks misrepresenting the risks associated with the product.